# Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients

> **NCT03359499** · PHASE2,PHASE3 · COMPLETED · sponsor: **Hospital Britanico** · enrollment: 80 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Bacillus clausii
- **DRUG:** Trimebutine

## Key facts

- **NCT ID:** NCT03359499
- **Lead sponsor:** Hospital Britanico
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-12
- **Primary completion:** 2017-10-25
- **Final completion:** 2017-11-23
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2018-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03359499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03359499, "Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03359499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*